Zhi-Cheng Li1, Hongmin Bai2, Qiuchang Sun1, Qihua Li1, Lei Liu1, Yan Zou3, Yinsheng Chen4, Chaofeng Liang5, Hairong Zheng1. 1. Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. 2. Department of Neurosurgery, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China. 3. Department of Radiology, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 4. Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. chenyinsh@sysucc.org.cn. 5. Department of Neurosurgery, The 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. lcfjeff@126.com.
Abstract
OBJECTIVES: To build a reliable radiomics model from multiregional and multiparametric magnetic resonance imaging (MRI) for pretreatment prediction of O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status in glioblastoma multiforme (GBM). METHODS: In this retrospective multicentre study, 1,705 multiregional radiomics features were automatically extracted from multiparametric MRI. A radiomics model with a minimal set of all-relevant features and a radiomics model with univariately-predictive and non-redundant features were built for MGMT methylation prediction from a primary cohort (133 patients) and tested on an independent validation cohort (60 patients). Predictive models combing clinical factors were built and evaluated. Both radiomics models were assessed on subgroups stratified by clinical factors. RESULTS: The radiomics model with six all-relevant features allowed pretreatment prediction of MGMT methylation (AUC=0.88, accuracy=80 %), which significantly outperformed the model with eight univariately-predictive and non-redundant features (AUC=0.76, accuracy=70 %). Combing clinical factors with radiomics features did not benefit the prediction performance. The all-relevant model achieved significantly better performance in stratified analysis. CONCLUSIONS: Radiomics model built from multiregional and multiparameter MRI may serve as a potential imaging biomarker for pretreatment prediction of MGMT methylation in GBM. The all-relevant features have the potential of offering better predictive power than the univariately-predictive and non-redundant features. KEY POINTS: • Multiregional and multiparametric MRI features reliably predicted MGMT methylation in multicentre cohorts. • All-relevant imaging features predicted MGMT methylation better than univariately-predictive and non-redundant features. • Combing clinical factors with radiomics features did not benefit the prediction performance.
OBJECTIVES: To build a reliable radiomics model from multiregional and multiparametric magnetic resonance imaging (MRI) for pretreatment prediction of O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation status in glioblastoma multiforme (GBM). METHODS: In this retrospective multicentre study, 1,705 multiregional radiomics features were automatically extracted from multiparametric MRI. A radiomics model with a minimal set of all-relevant features and a radiomics model with univariately-predictive and non-redundant features were built for MGMT methylation prediction from a primary cohort (133 patients) and tested on an independent validation cohort (60 patients). Predictive models combing clinical factors were built and evaluated. Both radiomics models were assessed on subgroups stratified by clinical factors. RESULTS: The radiomics model with six all-relevant features allowed pretreatment prediction of MGMT methylation (AUC=0.88, accuracy=80 %), which significantly outperformed the model with eight univariately-predictive and non-redundant features (AUC=0.76, accuracy=70 %). Combing clinical factors with radiomics features did not benefit the prediction performance. The all-relevant model achieved significantly better performance in stratified analysis. CONCLUSIONS: Radiomics model built from multiregional and multiparameter MRI may serve as a potential imaging biomarker for pretreatment prediction of MGMT methylation in GBM. The all-relevant features have the potential of offering better predictive power than the univariately-predictive and non-redundant features. KEY POINTS: • Multiregional and multiparametric MRI features reliably predicted MGMT methylation in multicentre cohorts. • All-relevant imaging features predicted MGMT methylation better than univariately-predictive and non-redundant features. • Combing clinical factors with radiomics features did not benefit the prediction performance.
Authors: Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi Journal: Nat Rev Neurol Date: 2009-12-08 Impact factor: 42.937
Authors: Nicholas J Tustison; Brian B Avants; Philip A Cook; Yuanjie Zheng; Alexander Egan; Paul A Yushkevich; James C Gee Journal: IEEE Trans Med Imaging Date: 2010-04-08 Impact factor: 10.048
Authors: Haruka Itakura; Achal S Achrol; Lex A Mitchell; Joshua J Loya; Tiffany Liu; Erick M Westbroek; Abdullah H Feroze; Scott Rodriguez; Sebastian Echegaray; Tej D Azad; Kristen W Yeom; Sandy Napel; Daniel L Rubin; Steven D Chang; Griffith R Harsh; Olivier Gevaert Journal: Sci Transl Med Date: 2015-09-02 Impact factor: 17.956
Authors: Jyrki Mp Lötjönen; Robin Wolz; Juha R Koikkalainen; Lennart Thurfjell; Gunhild Waldemar; Hilkka Soininen; Daniel Rueckert Journal: Neuroimage Date: 2009-10-24 Impact factor: 6.556
Authors: Ji Eun Park; Donghyun Kim; Ho Sung Kim; Seo Young Park; Jung Youn Kim; Se Jin Cho; Jae Ho Shin; Jeong Hoon Kim Journal: Eur Radiol Date: 2019-07-26 Impact factor: 5.315
Authors: Prathyush Chirra; Patrick Leo; Michael Yim; B Nicolas Bloch; Ardeshir R Rastinehad; Andrei Purysko; Mark Rosen; Anant Madabhushi; Satish E Viswanath Journal: J Med Imaging (Bellingham) Date: 2019-06-14
Authors: Evi J van Kempen; Max Post; Manoj Mannil; Benno Kusters; Mark Ter Laan; Frederick J A Meijer; Dylan J H A Henssen Journal: Cancers (Basel) Date: 2021-05-26 Impact factor: 6.639